DK
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
2 agencies contacted
Activity
filings by quarter
Works on
Specific issues
H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act.
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries.